KR20110017874A - 오래 작용하는 ｙ２ 및／또는 ｙ４ 수용체 작용제 - Google Patents

오래 작용하는 ｙ２ 및／또는 ｙ４ 수용체 작용제 Download PDF

Info

Publication number
KR20110017874A
KR20110017874A KR1020107027495A KR20107027495A KR20110017874A KR 20110017874 A KR20110017874 A KR 20110017874A KR 1020107027495 A KR1020107027495 A KR 1020107027495A KR 20107027495 A KR20107027495 A KR 20107027495A KR 20110017874 A KR20110017874 A KR 20110017874A
Authority
KR
South Korea
Prior art keywords
ethoxy
xaa
seq
acid
acetylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107027495A
Other languages
English (en)
Korean (ko)
Inventor
소렌 오스터가드
산네 몰러 크누드센
제인 스페츨러
라스무스 조르젠센
제이콥 코포이드
Original Assignee
노보 노르디스크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노보 노르디스크 에이/에스 filed Critical 노보 노르디스크 에이/에스
Publication of KR20110017874A publication Critical patent/KR20110017874A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020107027495A 2008-05-16 2009-05-18 오래 작용하는 ｙ２ 및／또는 ｙ４ 수용체 작용제 Withdrawn KR20110017874A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08156360 2008-05-16
EP08156360.3 2008-05-16
EP09154461 2009-03-05
EP09154461.9 2009-03-05

Publications (1)

Publication Number Publication Date
KR20110017874A true KR20110017874A (ko) 2011-02-22

Family

ID=40934036

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107027495A Withdrawn KR20110017874A (ko) 2008-05-16 2009-05-18 오래 작용하는 ｙ２ 및／또는 ｙ４ 수용체 작용제

Country Status (12)

Country Link
US (1) US20110275559A1 (cg-RX-API-DMAC10.html)
EP (1) EP2279204A1 (cg-RX-API-DMAC10.html)
JP (1) JP2011520847A (cg-RX-API-DMAC10.html)
KR (1) KR20110017874A (cg-RX-API-DMAC10.html)
CN (1) CN102027007A (cg-RX-API-DMAC10.html)
AU (1) AU2009248041B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0912615A2 (cg-RX-API-DMAC10.html)
CA (1) CA2723855A1 (cg-RX-API-DMAC10.html)
IL (1) IL208836A0 (cg-RX-API-DMAC10.html)
MX (1) MX2010011845A (cg-RX-API-DMAC10.html)
RU (1) RU2504550C2 (cg-RX-API-DMAC10.html)
WO (1) WO2009138511A1 (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2450374B9 (en) 2009-07-02 2016-11-23 Takeda Pharmaceutical Company Limited Peptide and use thereof
CN102573888A (zh) * 2009-09-18 2012-07-11 诺和诺德公司 长效y2 受体激动剂
EP2498800A1 (en) * 2009-11-13 2012-09-19 Novo Nordisk A/S Long-acting y2 receptor agonists
GB201001333D0 (en) * 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
WO2012006566A2 (en) 2010-07-09 2012-01-12 Amylin Pharmaceuticals, Inc. Microcrystalline y receptor agonists
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
RS58039B1 (sr) 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
EP2842965A1 (en) 2013-09-03 2015-03-04 Gubra ApS Neuromedin U analogs comprising serum albumin binding amino acid residue
WO2015071355A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof
ES2732015T3 (es) * 2013-11-15 2019-11-20 Novo Nordisk As Compuestos de PYY selectivos y sus usos
WO2015073878A1 (en) * 2013-11-15 2015-05-21 Ur Diet, Llc Real-time satiety biofeedback
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
US20240100450A9 (en) * 2014-01-17 2024-03-28 Repligen Corporation Sterilizing chromatography columns
EP3094391B1 (en) 2014-01-17 2024-11-20 Repligen Corporation Sterilizing chromatography columns
CN114805527A (zh) * 2014-05-21 2022-07-29 哈佛大学的校长及成员们 Ras抑制肽和其用途
MX392572B (es) * 2015-06-12 2025-03-24 Novo Nordisk As Compuestos del péptido yy (pyy) selectivos y sus usos.
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
TWI749381B (zh) * 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
GB201908426D0 (en) * 2019-06-12 2019-07-24 Imp College Innovations Ltd Appetite suppressing compounds
CA3175725A1 (en) * 2020-04-17 2021-10-21 William Blackwell Long acting peptide tyrosine tyrosine (pyy) analogs and methods of use
JP2024516395A (ja) 2021-04-27 2024-04-15 アードバーク・セラピューティクス・インコーポレイテッド 苦味受容体アゴニストおよび腸シグナル伝達化合物の組み合わせ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123293A3 (en) * 2000-12-14 2010-09-08 Amylin Pharmaceuticals, Inc. Peptide YY and petide YY agonists for treatment of metabolic disorders
EP1670515A2 (en) * 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1789440A4 (en) * 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM
DK2060266T3 (da) * 2004-03-17 2011-11-14 7Tm Pharma As Y4-selektiv receptoragonist PP2-36 til terapeutiske indgreb
ES2542228T3 (es) * 2004-07-08 2015-08-03 Novo Nordisk A/S Marcas de prolongación polipeptídica que comprenden un resto de tetrazol
CN101222942A (zh) * 2005-07-18 2008-07-16 诺沃-诺迪斯克有限公司 用于治疗肥胖的肽

Also Published As

Publication number Publication date
RU2504550C2 (ru) 2014-01-20
EP2279204A1 (en) 2011-02-02
BRPI0912615A2 (pt) 2016-01-26
MX2010011845A (es) 2010-11-22
AU2009248041A1 (en) 2009-11-19
CA2723855A1 (en) 2009-11-19
IL208836A0 (en) 2011-01-31
WO2009138511A1 (en) 2009-11-19
US20110275559A1 (en) 2011-11-10
AU2009248041B2 (en) 2013-10-03
CN102027007A (zh) 2011-04-20
RU2010149474A (ru) 2012-06-27
JP2011520847A (ja) 2011-07-21

Similar Documents

Publication Publication Date Title
AU2009248041B2 (en) Long-acting Y2 and/or Y4 receptor agonists
AU2010203063B2 (en) Albumin-binding derivatives of therapeutic peptides
ES2672770T3 (es) Derivados del péptido-1 similar al glucagón y su uso farmacéutico
JP5209463B2 (ja) アシル化ｇｌｐ−１化合物
JP5755398B2 (ja) 伸長されたｇｌｐ−１化合物
US9657079B2 (en) Truncated GLP-1 derivatives and their therapeutical use
KR102255479B1 (ko) 인슐린 저항성에 대한 개선된 펩티드 제약
KR102213907B1 (ko) 인슐린 저항성에 대한 개선된 펩티드 약제
KR102505628B1 (ko) 글루카곤 및 glp-1 수용체의 장기-작용성 공-효능제
KR102512178B1 (ko) 개선된 펩티드 제약
JP2007537142A (ja) アルブミン様物質に結合した新規のｇｌｐ−１類似物
EP2477643A1 (en) Long-acting y2 receptor agonists
BR112012029248B1 (pt) Análogo de glp-1 de fórmula i ou a sua composição, análogo de glp-1 de fórmula viii ou um sal farmaceuticamente aceitável ou a composição do mesmo, composição farmacêutica e uso de um composto
CN102076353A (zh) 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽
RU2779314C2 (ru) Коагонисты рецепторов глюкагона и glp-1 длительного действия
TWI428139B (zh) A novel glucagon-like peptide analogue, a composition and use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101207

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140516

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20141006

WITB Written withdrawal of application